Candong, Princess Nadia .
HRN: 23-34-82 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/03/2024
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
06/03/2024
06/10/2024
ORAL
2ml
Q12
Bacterial Skin Infection
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes